Lead Optimization and Pre Clinical Development of Therapeutic Candidates for Diseases of Interest to NIDDK (STTR (R41/R42)) | Apply Online

Opportunity Summary:

The grant opportunity "Lead Optimization and Pre Clinical Development of Therapeutic Candidates for Diseases of Interest to NIDDK (STTR (R41/R42))" (Funding Opportunity Number PA 14 054) is a National Institutes of Health (NIH) program designed to help small businesses push promising therapeutic ideas beyond early discovery and into the kind of rigorous development work needed to reach an FDA submission. It sits within the mission space of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), meaning projects should directly target diseases and conditions aligned with NIDDK priorities, broadly covering diabetes, digestive diseases, nutrition-related conditions, and kidney and urologic diseases. The overall intent is practical and translational: support the work required to turn a research lead into a credible, development-ready therapeutic candidate.

This is an STTR mechanism, meaning it is structured around collaboration between a small business and a nonprofit research institution, with the goal of combining the companys product development focus with the scientific depth and infrastructure often found in academic or research settings. The funding instrument type is a grant, and the activity category is listed under food and nutrition health, with the associated CFDA number 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research). The announcement explicitly notes there is no cost sharing or matching requirement, which lowers the barrier for small companies that might not be able to commit substantial non-federal dollars during preclinical development.

The FOA is organized around two sequential phases that map to typical preclinical development. Phase I (R41) is meant to support preliminary steps needed for lead optimization or early preclinical development. In practical terms, this phase is where applicants would be expected to show that they can improve and validate a lead candidate in ways that make it more viable as a therapeutic. Depending on the modality, that can include early medicinal chemistry optimization, initial formulation development, establishing assays and screening funnels, selecting among candidate series, confirming mechanism-related activity, or generating early proof that the candidate has properties consistent with moving forward. The emphasis is on derisking and building a foundation for a more complete preclinical package rather than simply demonstrating basic scientific interest.

Phase II (R42) is intended to fund the more advanced and expensive development work needed to position a lead candidate for entry into clinical testing. The announcement sets a clear expectation that projects in Phase II must be advanced enough that, by the end of Phase II or Phase IIB (where applicable), the team can submit an Investigational New Drug (IND) application or an Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA). That statement is important because it signals what NIH expects the end product to look like: not just more data, but a development package that meets regulatory standards. Activities that typically fit this stage include more comprehensive pharmacology, dose ranging, safety and toxicology planning and execution (often under GLP where appropriate), pharmacokinetics and ADME work, CMC planning such as manufacturing scale-up and stability, and any device-specific verification and validation needed for an IDE path. The central idea is that by the end of Phase II, the project should have crossed the threshold from an experimental candidate to a defined product-ready program with a realistic regulatory submission path.

A defining feature of this opportunity is its emphasis on project management discipline. Applications are expected to include clear milestones and timelines, along with specific Go/No Go decision points. That requirement signals that NIDDK wants applicants to treat the project like a development program, not an open-ended research study. Milestones should be measurable and tied to decisions such as whether to advance a particular lead, whether to invest in expensive tox studies, or whether to pivot based on efficacy, safety, manufacturability, or other developability constraints. The expectation is that applicants will present a credible stepwise plan that shows how Phase I results will justify Phase II activities, and how Phase II activities will culminate in an IND or IDE submission.

Eligibility is focused on small businesses, consistent with the STTR program goals of stimulating commercialization and product development. Foreign (non-U.S.) entities are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible to apply. However, the FOA notes that foreign components, as defined under the NIH Grants Policy Statement, may be allowed in some circumstances, which can matter for situations like specialized testing capacity or unique resources located outside the U.S., as long as the applicant organization remains eligible and the arrangement fits NIH policy.

From an administrative timeline perspective, this opportunity was posted and created on January 2, 2014, with an original and current closing date of January 7, 2017, and an archive date of February 7, 2017. In other words, it is an archived FOA rather than a currently open one, but it remains useful as a reference for how NIDDK structures late discovery and preclinical development expectations under the STTR mechanism. The NIH listing also provides a link to the full announcement (http://grants.nih.gov/grants/guide/pa-files/PA-14-054.html) and general contact guidance through the NIH Office of Extramural Research (OER) for access or linking issues via FBOWebmaster@OD.NIH.GOV.

Overall, the opportunity is best understood as a bridge between discovery science and first-in-human readiness for NIDDK-relevant therapeutics. It funds the hard middle steps that often determine whether a candidate is truly developable, with a strong preference for proposals that are organized around concrete deliverables, explicit decision gates, and a realistic plan to reach an FDA IND or IDE submission by the end of Phase II.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Food and Nutrition Health

Next opportunity: Lead Optimization and Pre Clinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (SBIR (R43/R44))

Previous opportunity: OVW Fiscal Year 2014 Transitional Housing Assistance Grants for Victims of Domestic Violence, Dating Violence, Stalking or Sexual Assault Program

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 14 054

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 14 054) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 14 054", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.